Antibiotic Medications — Compared

Amoxicillin is the most prescribed antibiotic in the United States and one of the most widely used drugs in medicine. It is a semi-synthetic penicillin that works by inhibiting bacterial cell wall synthesis — specifically by binding to penicillin-binding proteins (PBPs) and blocking transpeptidation, the final cross-linking step in peptidoglycan construction. Without an intact cell wall, bacteria cannot maintain osmotic integrity and lyse.

Its spectrum covers many common community pathogens: streptococci (including Streptococcus pneumoniae and Streptococcus pyogenes), Haemophilus influenzae, Enterococcus faecalis, Escherichia coli, and others. It does not cover Staphylococcus aureus (most strains produce beta-lactamase that destroys it), Pseudomonas, or MRSA.

Amoxicillin is well absorbed orally (better than ampicillin), tolerates food, comes in multiple formulations including a pleasant-tasting pediatric suspension, and is inexpensive. These practical properties — not unique efficacy — explain its dominant prescription share.

Amoxicillin-clavulanate pairs amoxicillin with clavulanic acid, a beta-lactamase inhibitor (BLI). Many bacteria resist penicillins by producing beta-lactamase enzymes that break open the beta-lactam ring and inactivate the antibiotic. Clavulanate binds irreversibly to these enzymes, protecting the amoxicillin molecule and restoring its activity against beta-lactamase-producing organisms.

The combination extends coverage to include beta-lactamase-producing strains of Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus (MSSA), and many Enterobacteriaceae — making it a useful drug for infections where these organisms are likely, such as sinusitis, otitis media that failed plain amoxicillin, animal bites, and diabetic foot infections.

Cephalexin is a first-generation cephalosporin — a class structurally related to the penicillins but with a different side chain and broader utility in patients with non-severe penicillin allergy (the cross-reactivity rate is low, approximately 1–2%, and relates to the specific penicillin allergy mechanism rather than cephalosporins as a class). Like penicillins, cephalosporins inhibit bacterial cell wall synthesis.

First-generation cephalosporins provide excellent gram-positive coverage (streptococci, methicillin-sensitive Staphylococcus aureus) with limited gram-negative activity. Cephalexin is not effective against MRSA, Enterococcus, or Pseudomonas.

Ceftriaxone is a third-generation cephalosporin available only as an injectable (IV or IM) — there is no oral formulation. Its long half-life of approximately 8 hours allows once-daily dosing for most indications, a practical advantage in outpatient and inpatient settings alike.

Third-generation cephalosporins shift the spectrum substantially toward gram-negative organisms compared to first-generation drugs, while retaining useful gram-positive activity (including against Streptococcus pneumoniae, an important respiratory pathogen). Ceftriaxone penetrates the blood-brain barrier, making it a preferred agent for bacterial meningitis. It is the treatment of choice for gonorrhea following the emergence of fluoroquinolone-resistant strains.

Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and blocking translocation — the movement of the ribosome along the mRNA. This is bacteriostatic for most organisms (inhibiting growth without directly killing bacteria) and bactericidal at high concentrations against some pathogens.

Its defining pharmacokinetic feature is an exceptionally long tissue half-life of approximately 68 hours (much longer than the serum half-life), because azithromycin concentrates extensively in tissues and within cells — intracellular concentrations can exceed serum levels by 100-fold or more. This tissue accumulation explains why short courses (the famous 5-day "Z-Pak") achieve clinically adequate tissue exposure over 7–10 days even though the drug is taken for only 5 days.

Azithromycin does not cover Pseudomonas and has no activity against methicillin-resistant Staphylococcus aureus. Increasing macrolide resistance in Streptococcus pneumoniae limits its utility for pneumococcal pneumonia in regions with high resistance prevalence.

Clarithromycin shares azithromycin's macrolide mechanism but differs importantly in its drug interaction profile: it is a potent inhibitor of CYP3A4, one of the most important drug-metabolizing enzymes in the body. This means clarithromycin can substantially increase blood levels of dozens of other medications — statins (raising myopathy risk), certain immunosuppressants, some anticoagulants, and many others — requiring careful medication review before prescribing.

Its primary specialized use today is in combination regimens for Helicobacter pylori eradication (the bacterium responsible for most gastric ulcers) and for treatment and prophylaxis of Mycobacterium avium complex (MAC) infections in immunocompromised patients. Its bitter metallic taste is a common tolerability complaint.

Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV — enzymes that manage DNA supercoiling and are essential for DNA replication, transcription, and repair. Without these enzymes, bacteria cannot replicate and die. This mechanism is distinct from all beta-lactam, macrolide, and tetracycline antibiotics, making fluoroquinolones useful for organisms resistant to those classes.

Ciprofloxacin has excellent gram-negative coverage, including Pseudomonas aeruginosa — one of few oral antibiotics with reliable anti-pseudomonal activity. This makes it uniquely valuable for complicated urinary tract infections, certain respiratory infections in cystic fibrosis patients, and infections caused by resistant gram-negative bacilli. However, it has poor gram-positive coverage for organisms like Streptococcus pneumoniae and should not be relied upon for community-acquired pneumonia.

Levofloxacin is categorized as a "respiratory fluoroquinolone" — it has meaningfully better coverage of Streptococcus pneumoniae than ciprofloxacin, while retaining most of ciprofloxacin's gram-negative activity (though less reliable against Pseudomonas). This makes it suitable for community-acquired pneumonia, particularly when atypical organisms or drug-resistant pneumococci are considerations.

Once-daily dosing (versus twice-daily for ciprofloxacin in most indications) supports adherence. It is available in tablet and IV forms with near-equivalent oral bioavailability, allowing seamless transition from IV to oral therapy in hospitalized patients — a practical advantage that can shorten hospital stays.

Doxycycline binds reversibly to the 30S ribosomal subunit and blocks the attachment of aminoacyl-tRNA to the ribosomal acceptor site — preventing elongation of the peptide chain and thereby halting protein synthesis. This is primarily bacteriostatic: it stops bacterial growth and relies on the immune system to clear the infection.

Doxycycline's spectrum is notably broad for a single agent: it covers many gram-positive and gram-negative bacteria, atypical organisms (Chlamydia, Mycoplasma, Legionella), rickettsial organisms, spirochetes (Borrelia burgdorferi, the cause of Lyme disease), and even has activity against some MRSA strains. This versatility, combined with good oral bioavailability, twice-daily dosing, and low cost, makes it a workhorse antibiotic for a wide range of outpatient infections.

Minocycline shares doxycycline's tetracycline mechanism but is the most lipophilic member of the class — it penetrates tissues, including the central nervous system and sebaceous glands, more readily than other tetracyclines. This lipophilicity is what makes it particularly effective for acne, where it reaches the sebaceous units where Cutibacterium acnes resides.

Unlike doxycycline, minocycline has a notable vestibular side effect profile: dizziness, vertigo, and ataxia occur more frequently, particularly early in treatment and at higher concentrations. These effects are dose-dependent and reversible on discontinuation. Prolonged use can cause blue-grey discoloration of skin, teeth, and mucous membranes, and rare cases of drug-induced lupus erythematosus have been reported.

Metronidazole is a nitroimidazole that works by entering susceptible cells, where anaerobic conditions reduce its nitro group to form toxic reactive intermediates. These intermediates disrupt DNA, causing strand breakage and rapid cell death. Crucially, this activation requires anaerobic or microaerophilic conditions — aerobic bacteria lack the reducing environment needed to activate metronidazole, explaining its selective activity against anaerobes and certain protozoa (Giardia, Trichomonas, Entamoeba).

Metronidazole is a standard component of triple therapy for H. pylori eradication and remains active against C. difficile (though oral vancomycin is now preferred for most C. diff cases). Its CNS penetration makes it useful for brain abscesses caused by anaerobic organisms.

Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at a site near (but distinct from) the macrolide binding site. This binding blocks peptide bond formation — a bacteriostatic effect for most organisms. Unlike macrolides, clindamycin has excellent anaerobic coverage alongside gram-positive activity, and it reaches high concentrations in bone — making it valuable for osteomyelitis.

Clindamycin is active against community-acquired MRSA strains, making it a useful oral option for MRSA skin and soft tissue infections when TMP-SMX is not appropriate. It is an alternative for dental infections in penicillin-allergic patients and commonly used in gynecologic infections involving anaerobes.

Vancomycin inhibits bacterial cell wall synthesis through a distinct mechanism from beta-lactams: rather than binding to enzymes (PBPs), it binds directly to the D-Ala–D-Ala terminus of peptidoglycan precursors, physically blocking transglycosylation and transpeptidation. This different binding target means vancomycin remains active against MRSA, which resists beta-lactams by expressing an altered PBP.

Intravenous vancomycin is the primary systemic treatment for serious MRSA infections — bacteremia, endocarditis, meningitis, osteomyelitis. Oral vancomycin, however, is not absorbed from the GI tract and circulates only in the bowel lumen — making oral vancomycin appropriate exclusively for C. difficile colitis, where the target infection is in the bowel.

Linezolid inhibits protein synthesis by a unique mechanism: it binds to the 23S ribosomal RNA of the 50S subunit and prevents formation of the 70S initiation complex — the very first step of translation. Because this binding site differs from other ribosomal antibiotics, linezolid retains activity against organisms resistant to macrolides, tetracyclines, and clindamycin.

It is active against vancomycin-resistant Enterococcus (VRE), MRSA, and other multi-drug-resistant gram-positive organisms. Oral bioavailability approaches 100%, making the oral and IV forms clinically equivalent — a rare property that allows step-down to oral therapy without loss of efficacy, potentially reducing hospital stays for serious infections.